Pravin U. Dugel, MD, discusses results from the 2-year OASIS study, which evaluated the long-term efficacy and safety of ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT), including full thickness macular hole formation. Dr. Dugel explains the study's key efficacy endpoints and outlines the results of pharmacological VMA or VMT resolution after 28 days and throughout the 2-year follow-up period. Full safety information can be found here .
Ocriplasmin • vitreomacular adhesion, VMA
1 / 1 Series: Thrombogenics